L-Ornithine L-Aspartate Powder Suppliers & Bulk Manufacturers
Available Forms: Powder for Reconstitution for oral use
Available Strengths: 5 g, 10 g, or 15 g
Reference Brands: Liv.52, HepaMerz(EU)
Category:
Gastrointestinal Drugs
L-Ornithine L-Aspartate enhances hepatic ammonia detoxification by stimulating urea cycle activity in the liver. It helps reduce blood ammonia levels, supports liver function, and manages hepatic encephalopathy. Benefits include improved mental clarity, reduced neurotoxicity, and enhanced liver detoxification, supporting overall liver health and function.
L-Ornithine L-Aspartate powder is available in Powder for Reconstitution for oral use
and strengths such as 5 g, 10 g, or 15 g.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, L-Ornithine L-Aspartate powder is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
L-Ornithine L-Aspartate powder can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
L-Ornithine L-Aspartate powder is used extensively in Europe for managing hepatic encephalopathy and supporting liver function. In the EU, it is regulated as a medicinal product with dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans submitted to EMA. In the US, it is mainly available as compounded or compounded formulations, with limited commercial products approved. Dossiers should include comprehensive clinical and safety data, manufacturing details, and quality controls. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence facilitates timely approval, safe use, and wider availability, supporting liver health management worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing